Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Telikibart, an antibody targeting IL-4Ralpha.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tabirafusp, an antibody targeting IL6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Surovatamig, an antibody targeting CD3D&CD3E × CD19.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sonesitatug, an antibody targeting Claudin 18.2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Omectatug, an antibody targeting Claudin 18.2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gulgafafusp, an antibody targeting GLP1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Drotokibart, an antibody targeting IL-4Ralpha.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Betinukibart, an antibody targeting IL-17A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Afimkibart, an antibody targeting TL1A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bavituximab, an antibody targeting Phosphatidylserine.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gevokizumab, an antibody targeting IL-1beta.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ficlatuzumab, an antibody targeting HGF.